Positions

Overview

  • Dr. Kulkarni received her medical training and internship at Bangalore Medical College and Research Institute following which she obtained a Masters in Public Health at Harvard T.H. Chan School of Public Health. She completed a residency in Internal Medicine at Wayne State University 2013. Dr. Kulkarni then completed a clinical and research fellowship in the Division of Pulmonary, Allergy and Critical Care medicine at UAB in 2016 and was appointed as faculty within this Division.

    Dr. Kulkarni currently serves as the Director of Interstitial Lung Disease Program at UAB and champions efforts to provide quality clinical care to patients with interstitial lung diseases at her center. As a member of the steering committee of ILD network at American College of Chest Physicians, she strives to promote education for early diagnosis and quality treatment of these patients within the community as well. Dr. Kulkarni is currently principal/co-investigator on clinical trials studying new therapeutics for ILD and her research focuses on developing imaging biomarkers to prognosticate and assess response to therapy among these patients.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial 2020
    2020 Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolutionJCI insight.  5. 2020
    2020 The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosisRespiratory Medicine.  161. 2020
    2019 Preoperative Evaluation of Patients With Interstitial Lung DiseaseChest.  156:826-833. 2019
    2019 Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patientsPLoS ONE.  14. 2019
    2019 Update in pulmonary fibrosis 2018American Journal of Respiratory and Critical Care Medicine.  200:292-300. 2019
    2019 Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  200:199-208. 2019
    2019 Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis 2019
    2017 Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosisJournal of Immunology.  199:1596-1605. 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survivalRespiratory Medicine.  115:33-38. 2016
    2016 Matrix remodeling in pulmonary fibrosis and emphysemaAmerican Journal of Respiratory Cell and Molecular Biology.  54:751-760. 2016
    2016 Flexible bronchoscopy is safe and effective in adult subjects supported with extracorporeal membrane oxygenation 2016
    2016 Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung diseaseAmerican Journal of Respiratory and Critical Care Medicine.  193:861-866. 2016
    2016 Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections 2016
    2016 Extracorporeal membrane oxygenation in adults: A practical guide for internistsCleveland Clinic Journal of Medicine.  83:373-384. 2016
    2015 Heme oxygenase-1 protects Corexit 9500ainduced respiratory epithelial injury across speciesPLoS ONE.  10. 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2014 Characteristics of patients with pulmonary venoocclusive disease awaiting transplantationAnnals of the American Thoracic Society.  11:1411-1418. 2014
    2013 Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxideAmerican Journal of Respiratory and Critical Care Medicine.  188:1407-1412. 2013

    Research Overview

  • As a clinician-scientist in the Pulmonary, Allergy and Critical Care Division at UAB, Dr. Kulkarni's area of excellence is in clinical and translational research in the field of idiopathic pulmonary fibrosis and other interstitial lung diseases. Her research is focused on developing imaging based as well as molecular biomarkers to prognosticate and assess response to therapy in patients with pulmonary fibrosis. She is currently principal investigator and co-investigator on clinical trials studying new therapeutics in interstitial lung diseases. She also serves as co-investigator of NIH studies focusing on translational investigations into the pathogenesis of idiopathic pulmonary fibrosis within the Division.
  • Principal Investigator On

  • Private Grant  awarded by CHIMERIX, INC. 2020 - 2022
  • Interstitial Lung Disease Early Detection Program  awarded by University of Chicago 2019 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD 2019 - 2022
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2020
  • Investigator On

  • Private Grant  awarded by GENKYOTEX SA 2020 - 2025
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2024
  • Private Grant  awarded by FIBROGEN, INC. 2020 - 2023
  • Private Grant  awarded by PRIME EDUCATION LLC 2020 - 2023
  • Private Grant  awarded by GALAPAGOS NV. 2020 - 2023
  • Private Grant  awarded by RESPIVANT SCIENCES, GMBH 2019 - 2022
  • Private Grant  awarded by ATYR PHARMA, INC. 2020 - 2022
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University 2019 - 2021
  • Private Grant  awarded by MALLINCKRODT ARD, INC 2018 - 2021
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018 - 2021
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2018 - 2020
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh 2017 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh 2018 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University 2018 - 2019
  • Private Grant  awarded by CELGENE CORPORATION 2018 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2019
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2015 - 2018
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2018
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2017
  • Full Name

  • Tejaswini Kulkarni